Profile data is unavailable for this security.
About the company
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
- Revenue in USD (TTM)0.00
- Net income in USD-36.01m
- Incorporated2020
- Employees50.00
- LocationMoonLake ImmunotherapeuticsDorfstrasse 29ZUG 6300SwitzerlandCHE
- Phone+41 415108022
- Websitehttps://moonlaketx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rhythm Pharmaceuticals Inc | 77.43m | -184.68m | 2.67bn | 226.00 | -- | 15.32 | -- | 34.46 | -3.19 | -3.19 | 1.34 | 2.86 | 0.2165 | 1.61 | 7.34 | 342,601.80 | -51.64 | -47.21 | -59.55 | -52.84 | 87.99 | -- | -238.52 | -681.38 | 5.43 | -- | 0.3847 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
Celldex Therapeutics, Inc. | 6.88m | -141.43m | 2.81bn | 160.00 | -- | 5.54 | -- | 407.55 | -2.91 | -2.91 | 0.1421 | 7.68 | 0.0168 | -- | 4.63 | 43,018.75 | -34.56 | -29.65 | -36.80 | -31.42 | -- | -- | -2,054.76 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
Arcellx Inc | 110.32m | -70.69m | 2.81bn | 130.00 | -- | 5.68 | -- | 25.45 | -1.49 | -1.49 | 2.30 | 9.28 | 0.1937 | -- | -- | 848,607.70 | -12.41 | -38.82 | -14.67 | -45.41 | -- | -- | -64.08 | -339.38 | -- | -- | 0.0749 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
ACADIA Pharmaceuticals Inc | 726.44m | -61.29m | 2.82bn | 597.00 | -- | 6.50 | -- | 3.88 | -0.3774 | -0.3774 | 4.43 | 2.62 | 1.09 | 1.96 | 9.05 | 1,216,812.00 | -9.17 | -27.50 | -12.81 | -32.73 | 94.27 | 95.62 | -8.44 | -38.35 | 2.28 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
Merus NV | 43.95m | -154.94m | 2.84bn | 172.00 | -- | 7.85 | -- | 64.58 | -2.99 | -2.99 | 0.8519 | 6.16 | 0.1056 | -- | 13.56 | 255,505.80 | -37.24 | -29.35 | -45.30 | -35.36 | -- | -- | -352.56 | -252.21 | -- | -- | 0.00 | -- | 5.68 | 2.75 | -18.10 | -- | -1.73 | -- |
MoonLake Immunotherapeutics | 0.00 | -36.01m | 2.89bn | 50.00 | -- | 5.52 | -- | -- | -0.7623 | -0.7623 | 0.00 | 8.20 | 0.00 | -- | -- | 0.00 | -14.61 | -- | -16.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
Azenta Inc | 641.02m | -17.37m | 2.98bn | 3.50k | -- | 1.22 | 42.62 | 4.65 | -0.2978 | -0.315 | 10.31 | 43.86 | 0.2096 | 2.86 | 3.40 | 183,149.40 | -0.568 | -0.5934 | -0.6169 | -0.6725 | 39.12 | 43.08 | -2.71 | -2.17 | 5.33 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
Immunocore Holdings PLC - ADR | 249.43m | -55.29m | 3.01bn | 497.00 | -- | 8.12 | -- | 12.07 | -1.13 | -1.13 | 4.99 | 7.42 | 0.4439 | 0.3994 | 5.82 | 501,867.20 | -9.84 | -27.55 | -12.51 | -36.82 | 99.58 | -- | -22.17 | -97.12 | 3.77 | -173.40 | 0.1152 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
Arrowhead Pharmaceuticals Inc | 181.74m | -296.81m | 3.03bn | 525.00 | -- | 16.38 | -- | 16.66 | -2.77 | -2.77 | 1.69 | 1.49 | 0.2395 | -- | -- | 346,171.40 | -39.91 | -20.02 | -46.61 | -24.65 | -- | -- | -166.63 | -61.79 | -- | -55.19 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
Apogee Therapeutics Inc | 0.00 | -83.99m | 3.06bn | 91.00 | -- | 6.89 | -- | -- | -1.74 | -1.74 | 0.00 | 7.86 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
Amicus Therapeutics, Inc. | 399.36m | -151.58m | 3.08bn | 517.00 | -- | 19.06 | -- | 7.71 | -0.5148 | -0.5148 | 1.35 | 0.5456 | 0.5318 | 0.8939 | 5.19 | 772,448.80 | -20.18 | -30.65 | -25.36 | -36.55 | 90.65 | 88.94 | -37.96 | -86.10 | 2.52 | -1.76 | 0.7077 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
Summit Therapeutics Inc | 0.00 | -614.93m | 3.08bn | 105.00 | -- | 39.65 | -- | -- | -1.54 | -1.54 | 0.00 | 0.1107 | 0.00 | -- | -- | 0.00 | -141.83 | -77.32 | -152.22 | -86.35 | -- | -- | -- | -20,989.46 | -- | -110.40 | 0.5628 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
Ideaya Biosciences Inc | 23.38m | -112.96m | 3.15bn | 124.00 | -- | 4.42 | -- | 134.86 | -1.96 | -1.96 | 0.4068 | 9.55 | 0.0451 | -- | 204.23 | 188,580.60 | -21.78 | -19.17 | -23.09 | -21.05 | -- | -- | -483.07 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 29 Feb 2024 | 21.75m | 36.29% |
Cormorant Asset Management LPas of 31 Dec 2023 | 8.49m | 14.17% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 3.79m | 6.32% |
Avoro Capital Advisor LLCas of 31 Dec 2023 | 2.58m | 4.30% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 2.31m | 3.86% |
Citadel Advisors LLCas of 31 Dec 2023 | 2.00m | 3.34% |
Adage Capital Management LPas of 31 Dec 2023 | 1.53m | 2.55% |
T. Rowe Price Investment Management, Inc.as of 31 Dec 2023 | 1.22m | 2.04% |
Federated Global Investment Management Corp.as of 31 Dec 2023 | 1.06m | 1.77% |
Darwin Global Management Ltd.as of 31 Dec 2023 | 1.04m | 1.73% |